Related Experiment Videos
Comparative safety of thrombolytic agents
1Cardiovascular Research Unit, Green Lane Hospital, Auckland, New Zealand.
Insights
For acute myocardial infarction (AMI), streptokinase, alteplase, and anistreplase offer similar benefits but differ in safety. Patient selection should consider adverse event risks and practical factors over perceived efficacy differences.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Thrombolytic therapy is crucial for acute myocardial infarction (AMI).
- Available agents include streptokinase, alteplase (tissue plasminogen activator), and anistreplase.
- These agents demonstrate comparable efficacy in preserving left ventricular function and reducing mortality post-AMI.
Purpose of the Study:
- To compare the safety profiles of available thrombolytic agents for acute myocardial infarction.
- To evaluate the incidence of adverse events associated with streptokinase, alteplase, and anistreplase.
- To inform clinical decision-making regarding thrombolytic agent selection based on risk-benefit assessment.
Main Methods:
- Review of clinical trial data comparing thrombolytic agents.
- Analysis of safety profiles, including cerebral hemorrhage, allergic reactions, and hypotension.
- Consideration of reinfarction rates associated with different agents.
- Reference to findings from the Third International Study of Infarct Survival (ISIS-3).
Main Results:
- Alteplase and anistreplase are associated with a high incidence of cerebral hemorrhage.
- Streptokinase has a low rate of cerebral hemorrhage but a higher risk of allergic reactions and hypotension.
- Alteplase shows a lower reinfarction rate compared to streptokinase and anistreplase.
- Hypotension is a risk with all agents, but more common with streptokinase and anistreplase.
Conclusions:
- Thrombolytic agents for AMI are equally effective, necessitating selection based on safety profiles.
- Patient-specific risk assessment for adverse events (e.g., hemorrhage, allergy) is paramount.
- Factors like cost and administration convenience may influence agent choice alongside safety.
Abstract:
Three available thrombolytic agents, streptokinase, alteplase, and anistreplase, have been shown to have similar effects on preservation of left ventricular function and mortality reduction after acute myocardial infarction (AMI). The agents are, however, quite different with respect to their safety profiles. Clinical trials to date suggest that alteplase (tissue plasminogen activator) or anistreplase administration is associated with a high incidence of cerebral hemorrhage. In contrast, streptokinase is associated with a low rate of cerebral hemorrhage. Streptokinase and anistreplase are associated with a higher risk of allergic reaction when compared with alteplase. Hypotension is also more common with streptokinase and anistreplase, but occurs significantly with alteplase as well. Alteplase is associated with a lower reinfarction rate when compared with streptokinase and anistreplase. The Third International Study of Infarct Survival (ISIS-3), a direct comparison of 3 thrombolytic agents (streptokinase, anistreplase, and duteplase), may provide some insight regarding the safety of these agents. Because these agents have been shown to be equally effective, selection of an appropriate agent for an individual patient may depend more on assessment of the likelihood of an adverse event or other factors, such as cost or convenience of administration, rather than assessment of the probability of greater benefit with a particular agent.